No menu items!

Covid-19: Anvisa authorizes study to measure efficacy of AstraZeneca 3rd dose

RIO DE JANEIRO, BRAZIL - Brazil's National Health Regulator (Anvisa) on Monday (19) authorized a study to measure the safety and efficacy of a third dose of AstraZeneca's Covid-19 vaccine, the regulatory agency said in a statement.

According to Anvisa, the study, sponsored by AstraZeneca, will be conducted with the participants of the initial research study who received the two doses of the vaccine four weeks apart. The third dose will be applied between 11 and 13 months after the second dose.

The study will be conducted only in Brazil with 10,000 volunteers in Bahia, Rio de . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?

Check out our other content